ARMP ARMP
Company Profile ↓Company Overview
ARMP (ARMP) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 79.5%, reflecting efficient use of shareholder capital.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +73.43% |
| 6 Months: | -39.35% |
| 3 Months: | -49.79% |
| 1 Month: | -11.49% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.62 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 79.5%.
CONS
- Trading 68.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 31.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -2.53M | -3.75M | -5.23M | -2.60M | -2.27M | -2.59M | -2.43M | -2.94M | -4.52M | -3.59M | -3.41M | -11.86M | -3.36M | -9.69M | -746.00K | -3.06M | -2.84M | -2.43M | -3.44M | -5.16M | -6.78M | -4.92M | -4.59M | -5.62M | -5.43M | -6.20M | -6.14M | -8.78M | -9.22M | -8.62M | -11.35M | -9.63M | -10.34M | -10.23M | -11.91M | -9.76M | -8.19M | -6.84M | -7.78M | -8.79M |
| Net Income | -11.31M | 13.87M | 21.21M | -664.00K | -14.49M | 10.77M | 5.44M | -2.23M | -3.11M | -3.85M | -2.38M | -9.50M | -3.25M | -6.46M | -779.00K | -3.13M | -3.17M | -2.77M | -3.74M | -4.20M | -6.96M | -5.08M | -4.71M | -5.77M | -5.50M | -6.19M | -5.42M | -8.77M | -9.21M | -8.61M | -14.49M | -3.55M | -31.16M | -25.02M | 8.99M | -5.48M | -6.53M | -16.30M | -26.68M | -115.35M |
| Diluted EPS | -3.18 | -0.63 | -0.86 | -0.44 | -3.49 | -0.33 | -0.30 | -0.54 | -0.82 | -7.82 | -3.23 | -0.76 | - | -1.46 | -0.09 | -0.24 | -0.68 | -0.60 | -0.11 | -0.69 | -0.73 | - | -0.26 | -0.31 | -0.27 | -0.25 | -0.22 | -0.30 | -0.26 | -0.24 | -0.40 | -0.17 | -0.86 | -0.69 | -0.25 | -0.15 | -0.20 | -0.45 | -0.74 | -3.16 |
| R&D Expense | 1.01M | 1.89M | 1.79M | - | 972.00K | 1.08M | 728.00K | - | 1.98M | 1.24M | 1.66M | - | 1.49M | 1.13M | - | 1.46M | 1.69M | 361.00K | 1.49M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -12.38M | -14.11M | -10.23M | -23.38M | -16.16M | -17.66M | -19.75M | -21.59M | -23.82M | -36.95M | -40.89M | -42.44M | -36.63M |
| Net Income | -64.58M | 23.11M | -516.00K | -18.84M | -12.84M | -16.70M | -19.48M | -22.18M | -23.16M | -36.92M | -69.05M | -18.92M | -173.80M |
| Diluted EPS | -0.64 | -2.33 | -1.99 | -24.67 | -2.18 | -3.59 | -2.55 | -1.35 | -0.96 | -1.08 | -1.91 | -0.89 | -4.80 |
| R&D Expense | 6.47M | 5.80M | 3.99M | 5.68M | 2.88M | 8.37M | 9.82M | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 41.21M | 28.62M | 31.49M | 18.15M | 11.14M | 14.54M | 25.45M | 39.52M | 69.77M | 95.83M | 98.36M | 86.44M | 76.88M |
| Total Equity | 12.94M | -22.62M | 3.44M | 12.71M | 9.72M | 24.34M | 7.69M | 14.59M | 18.86M | 25.40M | 36.08M | -32.06M | -48.02M | -218.60M |
| Cash & Equivalents | 862.00K | 20.36M | 6.58M | 9.37M | 5.71M | 5.13M | 9.66M | 6.03M | 9.65M | 10.29M | 14.85M | 13.52M | 9.29M | 8.69M |
| Total Liabilities | - | 63.13M | 23.19M | 6.89M | 8.43M | 3.41M | 6.85M | 10.86M | 20.66M | 44.37M | 59.75M | 130.43M | 134.46M | 295.48M |
| Current Liabilities | - | 2.39M | 1.87M | 2.38M | 3.54M | 1.97M | 2.03M | 4.88M | 6.71M | 4.81M | 24.87M | 16.46M | 48.25M | 8.95M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -10.61M | -9.19M | -10.63M | -15.58M | -18.27M | -23.57M | -32.48M | -47.42M | -37.55M | -25.76M |
| Investing Cash Flow | - | - | - | -279.00K | -58.00K | 8.81M | 2.88M | -824.00K | -1.30M | -2.21M | -8.13M | -1.88M | -542.00K |
| Financing Cash Flow | - | - | - | 7.23M | 8.67M | 12.45M | 8.97M | 23.21M | 25.52M | 44.02M | 53.99M | 34.96M | 25.61M |
| Capital Expenditure | -102.00K | -1.20M | -210.00K | -279.00K | -58.00K | -875.00K | -224.00K | -824.00K | -1.30M | -2.21M | -8.14M | -1.88M | -542.00K |
| Free Cash Flow | - | - | - | -10.88M | -9.25M | -11.50M | -15.81M | -19.09M | -24.88M | -34.69M | -55.57M | -39.43M | -26.30M |
| Dividends Paid | - | - | - | 80.00K | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 285.4% | 672.4% | -4.1% | -193.7% | -52.7% | -217.1% | -133.5% | -117.6% | -91.2% | -102.3% | 215.3% | 39.4% | 79.5% |
| ROCE % | -31.9% | -52.7% | -35.1% | -160.0% | -176.2% | -141.1% | -96.0% | -65.8% | -36.7% | -52.1% | -49.9% | -111.1% | -53.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARMP
Armata Pharmaceuticals, Inc. Actuals & Estimates (AMEX:ARMP) - TradingView
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNbTFTSnZWR0RPdlVkYVplS1F0WlNnd0J4ei0yeUQ3b2I2WEpCRGxNUXU3ZkVpblI3bzRuWXV4SjgzVWJzb3FTYWFqcmJ6WFRSN1JxOFZqX1NKSm5ES2hqZVJ4M0h0WWhSRllDMFBuczBmYzU0UzkyblctYjU4ak9LUlFUYw?oc=5" targe…
ARMATA PHARMACEUTICALS INC (ARMP) Stock Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE5TaTRWYU9wVDFDVWdxQVdZMUxyYk5CeEpvSHgtbEhuVWVlQ2tSZ3NhM0hKSmlDeHcweEJmV1c1bG9oMXFTZFRmeGg3WE9tWWNFN0t2RUoyeFdidmxIZl82eUFzX24?oc=5" target="_blank">ARMATA PHARMACEUTICALS INC (ARMP…
Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNU2psN1BLWWdFWk16YVp5Y1dTSWZoMTEwXzA5TjZ0MU5RRnc5NURYZjZRU25BRDJ0RVpaNTdadEQ2bG1DUHNNaTJrT0ttUlBsWGtkYkEyTkZyN3NxcEtNdmkwVEZDQlo3V2hMb0R6bFdYaWJHdUJXREJvNUctaFc0dG9iM0p1NGt3V1RITE…
Armata (ARMP) Names David House as New CFO to Lead Financial Str - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOYVlwRkJHa0xDaTF0U2ZIRXFxNUNtalpSU1NYUVlQdl81aTJDakpWeGpINGR3REVTUjNaYmJSMUxXcE4wcmR6d1ZXd0tfRVBRWHlqS0laM3ZWMk5VaURjRWdBbmFhRlBEbWdDaGdYWnU1V0c3ZHFxdmZ6WWFETUVHR2pQTnlaSGRuSEQ0UU…
ARMP Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBvMEVTT2h0X2hyVFA2b0ozM29obnJmNzRaSGZZb3N3dDlOQ0F6S1NfU1BhejVYRThVbUJINmlKUVBCRVBSSmEtZHpuOWhtczQzQXRFcVhUbjNhSkNsOUVVcFdRTHZtR203b2hnQXBMM2JhZHY5VnFz?oc=5" target="_blank">ARMP Fo…
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNWVdlRzRIeUpJVDdDTlhDRWtNYWxBeEstZmhYTzc3cVlxUjVWOURUMzBhXzZpWkVkaGR4VUJzTnFRMGdLUmk4TkEySVBvMXJOSUtaWm5INndtVzBpakJzUFVneFpudVNiYTFIRTNibl9qa19JN09KSEZsLURFbFFQb29TSHpNU0hWREhJLW…
ARMP — Frequently Asked Questions
What is the current share price of ARMP?
As of 2026-08-05 17:25 PDT, ARMP trades at $4.70 on NASDAQ/NYSE. Its 52-week range is $2.36 to $14.80.
What is the P/E ratio of ARMP?
ARMP trades at a trailing price-to-earnings (P/E) ratio of -0.98.
What is the return on equity (ROE) of ARMP?
ARMP has a return on equity (ROE) of 79.51%. Its return on capital employed (ROCE) is -53.93%.
Is ARMP a good stock to buy?
This page provides a data-driven analysis of ARMP, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.